Pfizer has acquired 50% stake in IGNITE Immunotherapy. Pursuant to the acquisition, Pfizer will hold 50% equity investment in IGNITE and be responsible for providing research and development funding for three years.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The acquisition will allow Pfizer to develop a new research programme to discover novel vaccinia viruses and also to expand its presence in the immuno-oncology field.
KDB Capital has acquired 6.7% stake in Anygen.
The acquirer is a financial services provider company, while the target is a peptide synthesis provider.
Image: Pfizer has acquired 50% stake in IGNITE Immunotherapy.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
